Skip the primary navigation if you do not want to read it as the next section.
Skip the main content if you do not want to read it as the next section.
IBE survey results reveal weight gain worry
The International Bureau for Epilepsy (IBE) has revealed in its latest survey that weight gain is most bothersome unwanted effect associated with epilepsy treatment.
The survey was funded through an unrestricted educational grant provided by the pharmaceutical company Eisai. Field work commenced this summer and will end in mid-September.
The survey marks the 50th anniversary of the IBE and the preliminary results, drawn from over 120 patients in 17 countries, show that weight gain is considered to be the most unwanted effect associated with epilepsy medication. Dizziness and slowing of mental agility were listed as being the next most disturbing unwanted effects.
Full survey results will be available before the end of the year.